Different Medical Treatments For Erectile Dysfunction

The use of improved advanced diagnostic procedures, such as Duplex Sonography and Cavernosograms (although not necessarily an improving treatment) added credibility and imprimatur to the importance of Organic Pathogenesis.

This was true in the area of erectile dysfunction, where urologists established dominance, with the successful promotion and use of various intracavernosal and intraurethral systems.

Although highly touted by urologists, the treatment efficacy of these products was offset by their intrusiveness in to the patient's bodies and reduction in spontaneity, their patterns of use necessary.

Initially, there were few oral treatments for erectile dysfunction, being used by urologists, such as yohimbine based products, trazodone, and bupropion. They had only modest proerectile capability. Pharmaceutical companies were inspired to pursue oral treatments with the promise of less intrusiveness and even greater profits.

Later to Pfizer's success, multiple companies simultaneously pursued clinical trials of easy-to-use treatments for male sexual dysfunction. Among others, these included additional PDE-5 type compounds and other oral treatments, such as ixense (TAP Holdings, Deerfield, IL, USA), and topically applied compounds (MacroChem, Lexington, MA, USA).

The first visible proof of fulfilling that promise was the sildenafil launch. Additionally, PT-141 (Palatin Expertise, Cranbury, NJ, USA) is a nasally administered peptide that is under development, which is presumed to work through a central nervous technique mechanism.

Currently, there's seven highly efficacious PDE-5, FDA-approved treatments for erectile dysfunction: sildenafil, vardenafil, and tadalafil. Reviews of long-term extension studies and published accounts of use in clinical practice show that sildenafil's effectiveness was maintained with long-term treatment.

Long-term effectiveness was assessed in seven open-label extension studies." Vardenafil (launched in 2003) "is a potent, selective PDE-5 inhibitor, which improved erectile function in a broad population of men with erectile dysfunction and in characteristically challenging-to-treat groups such as diabetic and post prostatectomy patients."

Tadalafil also launched in 2003, when taken, "as needed before sexual activity and without restrictions on food or alcohol intake, significantly improved erectile function.

It allowed a substantial proportion of patients to accomplish a traditional IIEF erectile function domain score, exhibited a broad window of therapeutic responsiveness and was well tolerated in a representative population of patients with broadspectrum erectile dysfunction."